Cargando…
PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431416/ http://dx.doi.org/10.1097/01.HS9.0000850920.41716.f0 |
| _version_ | 1784780049159815168 |
|---|---|
| author | Hultcrantz, M. Kleinman, D. Ghataorhe, P. Mckeown, A. He, W. Ling, T. Jewell, R. C. Byrne, J. Eliason, L. Scott, E. Opalinska, J. |
| author_facet | Hultcrantz, M. Kleinman, D. Ghataorhe, P. Mckeown, A. He, W. Ling, T. Jewell, R. C. Byrne, J. Eliason, L. Scott, E. Opalinska, J. |
| author_sort | Hultcrantz, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431416 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314162022-08-31 PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 Hultcrantz, M. Kleinman, D. Ghataorhe, P. Mckeown, A. He, W. Ling, T. Jewell, R. C. Byrne, J. Eliason, L. Scott, E. Opalinska, J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431416/ http://dx.doi.org/10.1097/01.HS9.0000850920.41716.f0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Hultcrantz, M. Kleinman, D. Ghataorhe, P. Mckeown, A. He, W. Ling, T. Jewell, R. C. Byrne, J. Eliason, L. Scott, E. Opalinska, J. PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title | PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title_full | PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title_fullStr | PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title_full_unstemmed | PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title_short | PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 |
| title_sort | pb2022: exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: dreamm-14 |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431416/ http://dx.doi.org/10.1097/01.HS9.0000850920.41716.f0 |
| work_keys_str_mv | AT hultcrantzm pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT kleinmand pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT ghataorhep pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT mckeowna pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT hew pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT lingt pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT jewellrc pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT byrnej pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT eliasonl pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT scotte pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 AT opalinskaj pb2022exploringalternativedosingregimensofsingleagentbelantamabmafodotinonsafetyandefficacyinpatientswithrelapsedorrefractorymultiplemyelomadreamm14 |